3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion
Recruiting now · Phase 4 · Has a placebo group
Conditions studied: IUD
In brief
Intrauterine device (IUD) insertion is a common contraceptive procedure often associated with moderate to severe pain, particularly among nulliparous individuals. Current pain management strategies, such as over-the-counter analgesics, are frequently inadequate. Methoxyflurane, a short-acting, self-administered inhaled analgesic, has been shown to provide rapid and effective pain relief in acute and procedural settings. This study aims to evaluate whether 3 mL of inhaled Methoxyflurane (via Penthrox inhaler) improves patient satisfaction by reducing pain and anxiety during IUD insertion.
Key facts
- Study ID
- NCT07295054
- Run by
- Women's College Hospital
- People needed
- 110
- Starts
- 2026-04-27
- Expected to finish
- 2027-02-01
- Last updated by the study team
- 2026-05-11
Who can join
Age: 18 and older, up to 55. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Patients with a uterus.
- Ages 18 to 55 years.
- Undergoing any intrauterine device (IUD) insertion.
- English-speaking participants.
- Ability to use an inhaler device.
- Willing to receive a cervical block for their IUD insertion
You may not qualify if…
- Inability to provide informed consent.
- Confirmed pregnancy.
- Use of pain medication other than NSAIDs or acetaminophen (e.g., opioids, benzodiazepines, muscle relaxants) within 24 hours prior to the intervention.
- Use of cannabis within 24 hours prior to the intervention.
- Administration of misoprostol within 24 hours prior to the intervention.
- Altered level of consciousness due to any cause, including head injury, drugs, or alcohol.
- History of severe adverse reactions to Penthrox (methoxyflurane) or other halogenated anesthetic agents, or to any ingredient in the formulation (including non-medicinal ingredients or container components).
- Anatomical variance, such as distorted uterine cavity, bicornuate uterus, uterus didelphys, or cervical stenosis.
- Clinically significant renal and/or liver impairment.
- Known or genetic susceptibility to malignant hyperthermia.
- Clinically evident hemodynamic or cardiovascular instability, or respiratory depression.
- Not NPO according to hospital guidelines.
Where it is running
- Women's College Hospital — Toronto, Ontario, Canada (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.